potl.ai

Signals / HHS-NIH11

Data IntegrationData GovernanceETL / ELTDatabaseData Architecturegrant · government

Optimal Treatment Strategies for use of Anti-Obesity Medications (AOMs) in Children and Adolescents Research Coordinating Center (U24 Clinical Trial Not Allowed)

HHS-NIH11 · United States

What the organization said · quoted from the source

  • “The RCC will lead, manage, and harmonize efforts for the Consortium”
  • “providing leadership and expertise on statistical design and analysis”
  • “harmonizing data collection methods and use of common data elements”
  • “developing the database”
  • “conducting data management and data analyses for Consortium studies”

Full text of the listing is at the original posting. We keep an excerpt; we never edit it.

excerpt as fetched · 2003 chars
This Notice of Funding Opportunity (NOFO) invites applications for a Research Coordinating Center (RCC) to participate in a consortium of clinical centers that will test anti-obesity medication (AOM) treatment strategies for youth with obesity that maximize benefits and minimize risks of AOM use. Such intervention strategies should support the promotion of healthy growth and development; adequate nutritional status/intake, healthy eating and physical activity behaviors; mental health and well-being (e.g., body image, self-esteem, mood, etc.), and quality of life and be feasible to implement in clinical care settings. Priority areas include testing strategies to determine optimal developmental stage for AOM initiation, rate and amount of weight loss, AOM class, dose, frequency, and duration, and content and intensity of adjunct lifestyle therapies that may be imperative to ensure normal psychological and physical development and to potentially avoid lifelong dependence on AOMs. Investigators should also evaluate potential predictors of response/ nonresponse to various treatment strategies under evaluation. The clinical centers may conduct independent or multicenter trials but will collaborate on the development of protocols, use of common measures and data elements, use of a central laboratory and standardized procedures to collect data and biospecimens, and data analyses and manuscriptsThe RCC will lead, manage, and harmonize efforts for the Consortium including 1) providing management and administrative support; 2) providing leadership and expertise on statistical design and analysis, 3) providing research coordination with a central laboratory, 4) harmonizing data collection methods and use of common data elements, 5) developing the database; 6) conducting data management and data analyses for Consortium studies; and 7) fostering research collaborations. This NOFO uses a cooperative agreement mechanism (U24) and runs in parallel with a companion NOFO (RFA-DK-27-121).
AI Opportunity AnalysisGenerated by POTL from the public listing (claude-haiku-4-5). The organization did not say any of this. Confidence 85/100.

Problem, as we read it

HHS-NIH needs a Research Coordinating Center to manage and harmonize multi-site clinical trial data and biospecimens across a consortium testing anti-obesity medications in youth. The center must establish common data elements, centralized laboratory procedures, database development, and cross-site data analytics while fostering research collaboration.

Potential agent · Multi-Site Clinical Trial Data Harmonization & Management Agent

An AI/data agent could automate the ingestion, validation, and harmonization of data from multiple clinical sites using common data elements; manage laboratory and biospecimen workflows; flag protocol deviations and data quality issues; and generate standardized reports for cross-site analysis and collaboration.

Capabilities

  • Ingest data from multiple EDC systems and hospital EMRs using standardized HL7/FHIR APIs
  • Validate incoming data against common data element schemas and clinical trial protocols
  • Detect and flag missing, inconsistent, or out-of-range values in real time
  • Map and harmonize variables across different site collection methods
  • Track biospecimen chain of custody and storage location
  • Generate automated quality control dashboards by site
  • Support statistical pre-processing and dataset preparation for analysis
  • Produce standardized research collaboration reports and data summaries
  • Audit and log all data transformations for regulatory compliance

Inputs

  • EDC export files (SAS, CSV, XML)
  • Hospital EMR data (via API or SFTP)
  • Laboratory results feeds
  • Biospecimen inventory data
  • Protocol documents and common data element definitions
  • Site enrollment and visit tracking data

Outputs

  • Harmonized trial database (SQL/data warehouse)
  • Data quality and protocol compliance reports
  • Site-level and consortium-level summary statistics
  • Prepared analysis-ready datasets
  • Biospecimen audit trail and location reports
  • Real-time data dashboard (enrollment, completion, quality metrics)
  • Regulatory compliance documentation

Likely integrations

  • Electronic Data Capture (EDC) platforms (Medidata Rave, REDCap, Oracle Clinical)
  • Hospital EMR systems (Epic, Cerner, Allscripts)
  • Laboratory Information Systems (LIS) (Cerner LIS, Epic Beaker, LabVantage)
  • Biospecimen/tissue bank management systems (CBMS, Criobank)
  • Statistical software (R, SAS, Python)
  • Cloud data warehouse (Snowflake, BigQuery, Redshift)
  • HL7/FHIR standards for clinical data exchange

Where a person stays on the loop

Governance committee approval for data harmonization rules and common data element mappings; statistical leads and biostatisticians for analysis and manuscript generation; site PIs for validation of site-level data quality reports; IRB/compliance team for audit trails and regulatory documentation

Security and compliance

Clinical trial data involves Protected Health Information (PHI) under HIPAA; biospecimen data linked to participants requires 21 CFR Part 11 compliance (FDA regulations for electronic records); data must be de-identified or properly access-controlled; audit trails mandatory for FDA/NIH oversight; secure data transfer protocols required across multiple sites

Our reasoning

  • The listing explicitly defines a data harmonization and management function across independent or multicenter trials, indicating the organization understands it needs orchestrated data integration, not ad-hoc site-by-site collection. This is a structured, repeatable workflow suitable for automation.
  • The emphasis on 'common data elements,' 'central laboratory,' and 'standardized procedures' signals that the RCC must enforce schemas and governance—tasks where agents excel at scale, especially when ingesting data from heterogeneous clinical systems.
  • The consortium structure (multiple clinical centers with independent protocols but shared analysis) is a classic multi-site trial data challenge: each site will use different EMRs and collection methods, requiring continuous validation, mapping, and reconciliation—a labor-intensive process ripe for agent-driven automation.
  • Biospecimen tracking and laboratory workflows are operationally repetitive (receipt, storage, tracking, retrieval) and generate high-volume, structured events; an agent could automate chain-of-custody logging, alert on storage deviations, and reconcile inventory—reducing manual data entry and human error.
Data integration platformsLaboratory Information Systems (LIS)Electronic Data Capture (EDC)Statistical softwareData warehouseAPI integrationBiospecimen tracking systemsClinical trial outcomesPatient demographicsMedication dosing and timingAnthropometric measurements (weight, height, BMI)Psychological assessments (mood, body image, self-esteem)Laboratory test resultsBiospecimens (collection, storage, tracking)Lifestyle intervention dataQuality of life measures
HHS-NIH11 · Optimal Treatment Strategies for use of Anti-Obesity Medications (AOMs) in Children and Adolescents Research Coordinating Center (U24 Clinical Trial Not Allowed) — POTL Signals